ERBB2 and gastric cancer: The cost-effectiveness analysis has indicated that the incorporation of cadonilimab alongside standard chemotherapy for the initial management of HER-2-negative advanced gastric cancer may not be deemed a cost-effective choice in comparison to chemotherapy alone.